Evidence map›Paper›PMID 19708088›Full record

ReviewFEBS letters2009

The proteostasis boundary in misfolding diseases of membrane traffic.

Darren M Hutt, Evan T Powers, William E Balch

Open access · greenAbstract readReview
In one paragraph

Review in FEBS letters, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 86 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Pharmacoproteomics pinpoints HSP70 interaction for correction of the most frequent Wilson disease-causing mutant of ATP7B.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Hallmarks of therapeutic management of the cystic fibrosis functional landscape.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2015
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Darren M HuttDepartment of Cell Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. dhutt@scripps.edu
Evan T Powers
William E Balch
Scripps Research Institute · US

Funding

Restoration of mutant CFTR stability and functionR01DK051870 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BALCH, WILLIAM EDWARD · 1996 to 2020
$8.7M
Modulation of Lung Disease by Genetic/Epigenetic ProfilingR01HL095524 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI William Edward Balch · 2010 to 2026
$7.5M
ROLE OF RAB PROTEINS AND CA2+ IN VESICULAR TRANSPORTR01GM042336 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI BALCH, WILLIAM EDWARD · 1990 to 2011
$4.8M
Structure and Function of Guanine Nucleotide Dissociation InhibitorR01GM033301 · NIGMS · YALE UNIVERSITY · PI BALCH, WILLIAM EDWARD · 1985 to 2012
$4.6M
Proteomic Profiling of CFTR Protein InteractionR01HL079442 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI BALCH, WILLIAM EDWARD, YATES III, JOHN R · 2005 to 2014
$4.6M
A Multidisciplinary Analysis of Gelsolin Amyloid DiseaseR01AG018917 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI KELLY, JEFFERY W · 2002 to 2010
$4.2M
Understanding and Ameliorating Loss-of-Function Protein Misfolding DiseasesR01DK075295 · NIDDK · SCRIPPS RESEARCH INSTITUTE, THE · PI KELLY, JEFFERY W · 2006 to 2014
$3.9M
NHLBI NIH HHS HL079442NHLBI NIH HHS R01 HL079442NHLBI NIH HHS R01 HL095524NIA NIH HHS AG18917NIA NIH HHS R01 AG018917NIDDK NIH HHS DK51870NIDDK NIH HHS DK75295NIDDK NIH HHS R01 DK051870NIDDK NIH HHS R01 DK075295NIGMS NIH HHS GM33301NIGMS NIH HHS GM42336NIGMS NIH HHS R01 GM033301NIGMS NIH HHS R01 GM042336
6 · The paper itself

Abstract

Protein function is regulated by the proteostasis network (PN) [Balch, W.E., Morimoto, R.I., Dillin, A. and Kelly, J.W. (2008) Adapting proteostasis for disease intervention. Science 319, 916-919], an integrated biological system that generates and protects the protein fold. The composition of the PN is regulated by signaling pathways including the unfolded protein response (UPR), the heat-shock response (HSR), the ubiquitin proteasome system (UPS) and epigenetic programs. Mismanagement of protein folding and function during membrane trafficking through the exocytic and endocytic pathways of eukaryotic cells by the PN is responsible for a wide range of diseases that include, among others, lysosomal storage diseases, myelination diseases, cystic fibrosis, systemic amyloidoses such as light chain myeloma, and neurodegenerative diseases including Alzheimer's. Toxicity from misfolding can be cell autonomous (affect the producing cell) or cell non-autonomous (affect a non-producing cell) or both, and have either a loss-of-function or gain-of-toxic function phenotype. Herein, we review the role of the PN and its regulatory transcriptional circuitry likely to be operational in managing the protein fold and function during membrane trafficking. We emphasize the enabling principle of a 'proteostasis boundary (PB)' [Powers, E.T., Morimoto, R.T., Dillin, A., Kelly, J.W., and Balch, W.E. (2009) Biochemical and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78, 959-991]. The PB is defined by the combined effects of the kinetics and thermodynamics of folding and the kinetics of misfolding, which are linked to the variable and adjustable PN capacity found different cell types. Differences in the PN account for the versatility of protein folding and function in health, and the cellular and tissue response to mutation and environmental challenges in disease. We discuss how manipulation of the folding energetics or the PB through metabolites and pharmacological intervention provides multiple routes for restoration of biological function in trafficking disease.

Indexed as

Metabolic Networks and PathwaysCell MembraneHumansMetabolic DiseasesNeurodegenerative DiseasesProtein FoldingProteinsProtein TransportProteins

Identifiers

PMID19708088
PMCPMC2805282
OpenAlexW2169409747

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.